文献速递哮喘

美泊利单抗治疗重度哮喘中糖皮质激素依从性与临床结局

Adherence to corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma.
PubMed 文献 · Eur Respir J · 2020-05-07

本研究纳入91例完成1年美泊利单抗治疗的OCS依赖型重度嗜酸性哮喘患者,评估ICS依从性(MPR)与临床结局的关系。结果显示,68%患者ICS依从性良好,依从性良好者OCS减量幅度和年急性发作率改善均优于依从性差者。良好ICS依从性预测维持OCS停用可能性(调整OR 3.19,95%CI 1.02-9.94;p=0.045)。

要点

  • 美泊利单抗治疗期间68%患者ICS依从性良好,18%依从性差。
  • ICS依从性良好者OCS减量中位数100% vs 60%(p=0.031)。
  • ICS依从性良好者AER变化-2.1±3.1 vs 0.3±2.5(p=0.011)。

核心结论

  • 重度嗜酸性哮喘患者接受美泊利单抗治疗时ICS不依从常见,且与OCS需求及AER改善较少相关。

研究设计与样本

  • 回顾性队列分析,纳入109例开始美泊利单抗治疗的OCS依赖型重度嗜酸性哮喘患者,最终分析91例完成12个月治疗者。

主要发现

  • 美泊利单抗治疗期间68%患者ICS依从性良好,16例(18%)依从性差。
  • 队列ICS使用在治疗前(MPR 0.81±0.32)与治疗期间(0.82±0.32;p=0.78)相似。
  • 依从性良好者OCS减量中位数(IQR)100(74-100)% vs 60(27-100)%;p=0.031。
  • 依从性良好者AER变化-2.1±3.1 vs 0.3±2.5;p=0.011。
  • 良好ICS依从性预测停用维持OCS的可能性(调整OR 3.19,95%CI 1.02-9.94;p=0.045)。

关键数值与推荐

  • ICS依从性以药物占有比(MPR)评估:良好>0.75,中等0.74-0.51,差<0.5。

临床怎么用

  • 对接受美泊利单抗的重度嗜酸性哮喘患者,应评估并促进ICS依从性以优化OCS减量和急性发作控制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Inhaled corticosteroids (ICS) achieve disease control in the majority of asthmatic patients, although adherence to prescribed ICS is often poor. Patients with severe eosinophilic asthma may require treatment with oral corticosteroids (OCS) and/or biologic agents such as mepolizumab. It is unknown if ICS adherence changes on, or alters clinical response to, biologic therapy. METHODS: We examined ICS adherence and clinical outcomes in OCS-dependent severe eosinophilic asthma patients who completed 1 year of mepolizumab therapy. The ICS medicines possession ratio (MPR) was calculated (the number of doses of ICS issued on prescription/expected number) for the year before and the year after biologic initiation. Good adherence was defined as MPR >0.75, intermediate 0.74-0.51 and poor <0.5. We examined outcomes after 12 months of biologic therapy, including OCS reduction and annualised exacerbation rate (AER), stratified by adherence to ICS on mepolizumab. RESULTS: Out of 109 patients commencing mepolizumab, 91 who had completed 12 months of treatment were included in the final analysis. While receiving mepolizumab, 68% had good ICS adherence, with 16 (18%) having poor ICS adherence. ICS use within the cohort remained similar before (MPR 0.81±0.32) and during mepolizumab treatment (0.82±0.32; p=0.78). Patients with good adherence had greater reductions in OCS dose (median (interquartile range) OCS reduction 100 (74-100)% versus 60 (27-100)%; p=0.031) and exacerbations (AER change -2.1±3.1 versus 0.3±2.5; p=0.011) than those with poor adherence. Good ICS adherence predicted the likelihood of stopping maintenance OCS (adjusted OR 3.19, 95% CI 1.02-9.94; p=0.045). CONCLUSION: ICS nonadherence is common in severe eosinophilic asthma patients receiving mepolizumab, and is associated with a lesser reduction in OCS requirements and AER.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. d'Ancona G, Kavanagh J, Roxas C, et al. Adherence to corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma. Eur Respir J. 2020. PMID: 32060061. doi:10.1183/13993003.02259-2019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。